QIAGEN Clinical Insight (QCI) Interpret

Expedite variant interpretation and reporting in-house for any NGS panel, exome, or genome from your sequencing platform.

Features

  • Dynamic candidate disease identification and phenotype network for confident clinical exome interpretation
  • AMP- and ACMG-based variant classifications for every variant in over 70,000 phenotypes
  • Weekly updated manually curated literature for all variants to increase diagnostic yield and avoid spending time researching variants of unknown significance
  • Weekly updated clinical case information, therapeutic, prognostic, diagnostic evidence, including drug labels, recruiting clinical trials, practice guidelines, and clinical/functional studies
  • Access to >25 databases, including HGMD, COSMIC, ClinVar, gnomAD, AFC
S_1144_3_QDI_QCI_Interpret_GI1094847956

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

QCII 301-600 Genes 24 pck

Cat. No. / ID: 830729

24 QCI Interpret Test Analysis of up to 600 genes. To be used within 365 days.
Please note, this is a representative catalogue number - please inquire about other QCI Interpret options and configurations by using the inquire button below
The QIAGEN Clinical Insight (QCI) Interpret is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

Product Details

QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. Variant scientists and lab directors can confidently identify, prioritize and report on clinically relevant variants associated with hereditary cancer, sporadic cancer, inherited disorders, and rare and undiagnosed diseases without the time-consuming step of researching the latest publications and writing variant- and disease-specific evidence.

With over 2 decades of experience in clinical genomics interpretation in inherited diseases and oncology, QCI Interpret processes and interprets over 50,000 cases monthly and has interpreted more than 2.5 million samples for pathologists and lab directors.

Performance

QCI Interpret offers flexible and automatable interpretation workflows, powered by superior structured content in the QIAGEN Knowledge Base.
The application delivers content for interpretation of small variants such as SNVs, indels, duplications, frameshifts, exon level and larger copy number changes, fusions, rearrangements, TMB and MSI.
With QCI Interpret, you can reduce hands-on time with configurable and automatable NGS interpretation workflows. Plus, you can access preconfigured, ready-to-use workflows for QIAGEN and commercial NGS panels. The software also lets you customize your lab’s specific reporting policies to automate variant reporting and drug and trial selection, and you can leverage a feature-rich API to integrate with your LIMS to scale-up your case processing.

Applications

QCI Interpret is designed to augment in-house expertise by providing you with all of the content necessary to confidently identify disease causing or actionable variants and manually generate the report whereas the QCI API enables you to integrate content into your existing workflows for further processing.

Publications

Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer.
Winn JS; Hasse Z; Slifker M; Pei J; Arisi-Fernandez SM; Talarchek JN; Obeid E; Baldwin DA; Gong Y; Ross E; Cristofanilli M; Alpaugh RK; Fernandez SV;
Int J Mol Sci; 2020; 21 (4) 2020 Feb 14 PMID:32075053
The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B;
BMC Cancer; 2021; 21 (1):234 2021 Mar 6 PMID:33676450
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.
Rothwell DG; Ayub M; Cook N; Thistlethwaite F; Carter L; Dean E; Smith N; Villa S; Dransfield J; Clipson A; White D; Nessa K; Ferdous S; Howell M; Gupta A; Kilerci B; Mohan S; Frese K; Gulati S; Miller C; Jordan A; Eaton H; Hickson N; O'Brien C; Graham D; Kelly C; Aruketty S; Metcalf R; Chiramel J; Tinsley N; Vickers AJ; Kurup R; Frost H; Stevenson J; Southam S; Landers D; Wallace A; Marais R; Hughes AM; Brady G; Dive C; Krebs MG;
Nat Med; 2019; 25 (5):738-743 2019 Apr 22 PMID:31011204
Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling.
Mafficini A; Lawlor RT; Ghimenton C; Antonello D; Cantù C; Paolino G; Nottegar A; Piredda ML; Salvia R; Milella M; Dei Tos AP; Fassan M; Scarpa A; Luchini C;
Genes (Basel); 2021; 12 (4) 2021 Mar 26 PMID:33810291